$OCGN News

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Ocugen Executes Licensing Agreement With Roots Pharma And Its Strategic Partner Al-Dhow International For Exclusive Rights To OCU400 For Treatment Of Retinitis Pigmentosa In Middle East And North Africa Region

Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate

Transcript: Ocugen Q2 2026 Earnings Conference Call

Ocugen to Participate in Upcoming Scientific Conferences

Ocugen to Participate in Upcoming October Investor and Industry Conferences

Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

Ocugen Receives Bahamas Regulator Provisional Approval For OCU400 Has Been Granted Approval And Priority Designation; The Company Will Supply OCU400 Through An EAP, With Goal Of Treating First RP Patient Within 90 Days

Ocugen Targets Three Gene Therapy BLA Filings as Retinal Pipeline Advances

Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical

Ocugen: My Hold Rating Continued On OCU410ST Advancement And Upcoming Catalysts

What's Happening With Ocugen Stock Thursday?

HC Wainwright & Co. Maintains Buy on Ocugen, Lowers Price Target to $9.5

Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen Announces First Patient Dosed In Global Phase 3 Registrational Trial Of OCU410, Modifier Gene Therapy Candidate For GA Secondary To Dry Age-Related Macular Degeneration

Ocugen to Participate in Upcoming September Investor and Industry Conferences

Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts

Ocugen (OCGN) Q2 2026 Earnings Call Transcript